Home News Discussing the Management of KRAS Inhibitors in NSCLC back to News
minute read
During a Targeted Oncology Case-Based Roundtable event, D. Ross Camidge, MD, PhD, discussed dosing and toxicity concerns with the KRAS inhibitors adagrasib and sotorasib.
Topics: Press Coverage
1665 North Aurora Court
2004
Aurora, CO 80045
720-848-0300
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
